New study tracks daily life impact of CLL drug acalabrutinib
NCT ID NCT06548152
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 25 times
Summary
This study measures how chronic lymphocytic leukemia (CLL) patients feel and function while taking acalabrutinib in everyday life, not just in a controlled trial. Researchers will look at quality-of-life scores from treatment start up to 12 months later, using data from 120 French patients. The goal is to understand real-world benefits and challenges, helping doctors and patients make informed decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSaint-Affrique, France
Conditions
Explore the condition pages connected to this study.